Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHA:600488)
China · Delayed Price · Currency is CNY 7.20
-0.06 (-0.83%)
May 13, 2026, 3:00 PM CST
SHA:600488 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,730 | 2,908 | 3,190 | 3,755 | 3,666 | 3,735 |
Other Revenue | - | - | 25.76 | 27.48 | 22.56 | 13.35 |
| 2,730 | 2,908 | 3,215 | 3,783 | 3,689 | 3,749 | |
Revenue Growth (YoY) | -12.97% | -9.56% | -15.00% | 2.54% | -1.59% | 20.27% |
Cost of Revenue | 1,606 | 1,718 | 1,796 | 2,079 | 1,933 | 2,016 |
Gross Profit | 1,124 | 1,190 | 1,419 | 1,704 | 1,756 | 1,732 |
Selling, General & Admin | 749.4 | 751.63 | 930.58 | 1,337 | 1,394 | 1,385 |
Research & Development | 114.51 | 129.95 | 199.87 | 157.67 | 139.45 | 128.87 |
Other Operating Expenses | 5.27 | 6.54 | 18.53 | 29.44 | 40.9 | 40.15 |
Operating Expenses | 869.18 | 888.12 | 1,149 | 1,524 | 1,575 | 1,554 |
Operating Income | 255.26 | 301.78 | 269.96 | 179.93 | 181.37 | 178.2 |
Interest Expense | - | - | -28.82 | -36.69 | -48.16 | -45.91 |
Interest & Investment Income | - | - | 8.12 | 8.57 | 4.42 | 7.08 |
Earnings From Equity Investments | 0.8 | - | - | - | - | - |
Currency Exchange Gain (Loss) | - | - | 13.67 | 11.83 | 16.28 | 1.37 |
Other Non Operating Income (Expenses) | -89.25 | -82.78 | -1.18 | -0.92 | -1.86 | -2.54 |
EBT Excluding Unusual Items | 166.81 | 219 | 261.76 | 162.72 | 152.05 | 138.21 |
Gain (Loss) on Sale of Investments | -0.8 | -0.8 | -9.09 | -1.13 | -22.44 | - |
Gain (Loss) on Sale of Assets | -0 | 0.4 | -0.1 | 0.65 | -0.99 | -0.06 |
Asset Writedown | -101.9 | -96.49 | -34.56 | -8.18 | -73.02 | -4.37 |
Other Unusual Items | - | - | 8.5 | 14.18 | -43.1 | 15.29 |
Pretax Income | 64.1 | 122.11 | 226.51 | 168.24 | 12.52 | 149.07 |
Income Tax Expense | 2.25 | 0.05 | 18.3 | 5.57 | -5.92 | 40.4 |
Earnings From Continuing Operations | 61.85 | 122.05 | 208.21 | 162.67 | 18.44 | 108.67 |
Minority Interest in Earnings | -35.44 | -51.49 | -74.76 | -45.62 | 16.97 | -60 |
Net Income | 26.41 | 70.56 | 133.45 | 117.05 | 35.41 | 48.67 |
Net Income to Common | 26.41 | 70.56 | 133.45 | 117.05 | 35.41 | 48.67 |
Net Income Growth | -80.22% | -47.12% | 14.01% | 230.60% | -27.25% | 43.23% |
Shares Outstanding (Basic) | 1,079 | 1,086 | 1,094 | 1,094 | 1,106 | 1,082 |
Shares Outstanding (Diluted) | 1,079 | 1,086 | 1,094 | 1,094 | 1,106 | 1,082 |
Shares Change (YoY) | -1.38% | -0.75% | -0.01% | -1.13% | 2.31% | -1.33% |
EPS (Basic) | 0.02 | 0.07 | 0.12 | 0.11 | 0.03 | 0.04 |
EPS (Diluted) | 0.02 | 0.07 | 0.12 | 0.11 | 0.03 | 0.04 |
EPS Growth | -79.94% | -46.72% | 14.02% | 234.38% | -28.89% | 45.16% |
Free Cash Flow | 84.24 | 80.57 | 491.63 | 649.86 | 451.33 | -53.95 |
Free Cash Flow Per Share | 0.08 | 0.07 | 0.45 | 0.59 | 0.41 | -0.05 |
Dividend Per Share | - | - | 0.098 | 0.087 | 0.010 | 0.014 |
Dividend Growth | - | - | 12.64% | 770.00% | -28.57% | 40.00% |
Gross Margin | 41.18% | 40.92% | 44.13% | 45.04% | 47.61% | 46.21% |
Operating Margin | 9.35% | 10.38% | 8.40% | 4.76% | 4.92% | 4.75% |
Profit Margin | 0.97% | 2.43% | 4.15% | 3.09% | 0.96% | 1.30% |
Free Cash Flow Margin | 3.08% | 2.77% | 15.29% | 17.18% | 12.23% | -1.44% |
EBITDA | 552.45 | 597.35 | 559.08 | 450.78 | 438.18 | 383.2 |
EBITDA Margin | 20.23% | 20.54% | 17.39% | 11.92% | 11.88% | 10.22% |
D&A For EBITDA | 297.19 | 295.58 | 289.12 | 270.85 | 256.81 | 205 |
EBIT | 255.26 | 301.78 | 269.96 | 179.93 | 181.37 | 178.2 |
EBIT Margin | 9.35% | 10.38% | 8.40% | 4.76% | 4.92% | 4.75% |
Effective Tax Rate | 3.52% | 0.04% | 8.08% | 3.31% | - | 27.10% |
Revenue as Reported | - | - | 3,215 | 3,783 | 3,689 | 3,749 |
Advertising Expenses | - | - | 249.58 | 543.79 | 645.43 | 650.67 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.